Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine

Main|Search|PHGKB




Last Posted: Nov 30, 2018

---

• Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine
  JR Conway et al, Genome Medicine, November 30, 2018
• FDA approves ‘precision medicine’ drug for different cancers with same mutation
  L McGinley, Washington Post, November 26, 2018
• Cancer immunotherapy: challenges and clinical applications.
  Xia An-Liang et al. Journal of medical genetics 2018 Nov
• Precision medicine in head and neck cancer.
  Kaidar-Person Orit et al. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy 2018 Sep 4013-16
• Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation.
  Wu Xinyu et al. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2018 Nov
• RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications.
  Saeed Omer et al. Journal of clinical pathology 2018 Nov
• Evidence of response to pembrolizumab in a patient with Lynch syndrome-related metastatic colon cancer.
  Salman Pamela et al. OncoTargets and therapy 2018 117295-7300
• Prognostic Utility of Tumor-Infiltrating Lymphocytes in Noncolorectal Gastrointestinal Malignancies.
  Hamza Ameer et al. International journal of surgical pathology 2018 Nov 1066896918809460
• Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
  Dempke Wolfram C M et al. Translational lung cancer research 2018 Sep 7(Suppl 3) S275-S279
• Anti-PD-1/PD-L1 Therapy for Non-Small-Cell Lung Cancer: Toward Personalized Medicine and Combination Strategies.
  Sui Hongshu et al. Journal of immunology research 2018 20186984948

more